May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Compare and Evaluate the Efficacy and Safety of Intravitreal Injection of Bevacizumab, Ranibizumab and Pegaptanib Sodium in the Treatment of Choroidal Neovascularization in a Rat Model
Author Affiliations & Notes
  • F. Lu
    Ophthal & Visual Sci, Yale Univ School of Medicine, New Haven, Connecticut
  • R. Adelman
    Ophthal & Visual Sci, Yale Univ School of Medicine, New Haven, Connecticut
  • Footnotes
    Commercial Relationships F. Lu, None; R. Adelman, Consultant, C.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1461. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Lu, R. Adelman; Compare and Evaluate the Efficacy and Safety of Intravitreal Injection of Bevacizumab, Ranibizumab and Pegaptanib Sodium in the Treatment of Choroidal Neovascularization in a Rat Model. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1461.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To study the efficacy and safety of Intravitreal Injection of bevacizumab ( Avastin®), pegaptanib sodium (Macugen®) and ranibizumab (LucentisTM) in the treatment of choroidal neovascularization (CNV) in a rat model.

Methods:: Multiple CNV lesions were induced by laser photocoagulation of the retina in Norway-Brown rats. After 3 weeks, 14 rats were divided into three groups and received intravitreal injection of bevacizumab, pegaptanib sodium and ranibizumab in different dosage respectively. Some of the lesions received second treatment on day 14. The lesions were evaluated by fluorescein angiography 1, 7, 14 and 28 days later to assess the efficacy of these medications.

Results:: The dosage of bevacizumab in the treatment of CNV in rat model ranged from 0.025mg to 0.25mg. All of them did not show any effect in stopping the angiographic leakage in fluorescein angiography through day 28. Ranibizumab (0.012mg-0.06mg) and pegaptanib sodium (0.01mg) did not stop the leakage of CNV either. Second treatment of bevacizumab and pegaptanib sodium did not affect. There was no local and systemic side effect observed in rats.

Conclusions:: All of these three anti VEGF agents did not show any treatment effect in stopping laser-induced CNV leakage in rat. Our previous experiment with ranibizumab in monkeys resulted in significant decrease in leakage. The difference might be because ranibizumab is a humanized antibody and there is a difference between human and rat.

Keywords: age-related macular degeneration • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×